STOCK TITAN
  1. Home
  2. News
  3. IDYA

Ideaya Biosciences Inc - IDYA STOCK NEWS

Welcome to our dedicated news page for Ideaya Biosciences (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ideaya Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ideaya Biosciences's position in the market.

News
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Rhea-AI Summary
IDEAYA Biosciences announces ASCO 2024 oral presentation for Darovasertib in neoadjuvant uveal melanoma phase 2 investigator-sponsored study. The presentation is scheduled for June 3, 2024, at 9:51 AM CDT, with abstract summary available on May 23, 2024, at 5:00 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Rhea-AI Summary
IDEAYA Biosciences selects move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC based on promising clinical efficacy and adverse event profile. The company aims to address the high unmet medical need in this patient population and advance multiple rational combinations with pharma collaborators and internal pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
IDEAYA Biosciences, Inc. grants 70,000 non-qualified stock options to new employees under the 2023 Inducement Plan. The options have an exercise price of $43.88 per share, a 10-year term, and will vest over four years. This move aims to incentivize and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
News
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) will be participating in the Stifel Virtual Targeted Oncology Forum on April 16th, 2024. The event will feature a fireside chat with CEO Yujiro S. Hata. A live audio webcast will be available on the company's website, with replays accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
-
News
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
Rhea-AI Summary
IDEAYA Biosciences collaborates with Merck to evaluate IDE161 in combination with KEYTRUDA in endometrial cancer patients. IDE161 shows promising results in Phase 1 trials for various solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
News
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) announces participation in upcoming investor relations events including Leerink Partners Global Biopharma Conference and Jefferies Biotech on the Bay Summit. CEO Yujiro S. Hata will engage in discussions on targeted therapeutics and oncology advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
News
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) targets multiple clinical updates and collaborations in 2024, with a strong cash balance of $632.6 million. The company aims to advance darovasertib, IDE397, and AMG 193 programs, focusing on precision oncology and addressing unmet medical needs. Key developments include positive Phase 2 results for darovasertib and crizotinib combination, IND-filing targets, and new collaborations with Gilead Sciences and Amgen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
earnings
-
News
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
Rhea-AI Summary
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in upcoming investor relations events, including the Oppenheimer 34th Annual Healthcare Life Sciences Conference and Citi's 2024 Virtual Oncology Leadership Summit. The company's executives will engage in fireside chats to discuss the company's progress and future plans. The events will be live-streamed on the IDEAYA website, allowing investors and stakeholders to access the discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences
-
News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) granted 123,000 non-qualified stock options to three newly hired employees under the 2023 Inducement Plan. The options have an exercise price of $42.50 per share, with a 10-year term and will vest over four years. The announcement was made on January 25, 2024, as an inducement for the employees' entering into employment with IDEAYA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
News
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
Rhea-AI Summary
IDEAYA Biosciences, a precision medicine oncology company (NASDAQ: IDYA), announced participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance. The company has a balance sheet of $511.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023, and anticipates funding operations into 2028. IDEAYA also provided updates on its clinical programs, including potential registration-enabling Phase 2/3 clinical trials, clinical efficacy updates, and ongoing enrollment in various studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock IDYA logo
Ideaya Biosciences Inc

Nasdaq:IDYA

IDYA Rankings

#1553 Ranked by Market Cap
#381 Ranked by Stock Gains
N/A Ranked by Dividends

IDYA Stock Data

3.13B
73.78M
0.98%
102.9%
12.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About IDYA

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.